Variables | Total | Event-free group (n = 21) | Adverse cardiac event group (n = 20) | p-value |
---|---|---|---|---|
Clinical characteristics | ||||
Age, years | 47.0 ± 11.64 | 48.8 ± 10.0 | 45.2 ± 13.2 | 0.32 |
Male gender, n (%) | 33 (80) | 18 (86) | 15 (75) | 0.42 |
NYHA III-IV class, n (%) | 36 (88) | 17 (81) | 19 (95) | 0.34 |
Systolic BP, mm Hg | 114 (104, 130) | 120 (110, 130) | 110 (103, 120) | 0.09 |
Diastolic BP, mm Hg | 80 (70, 80) | 80 (70, 80) | 73 (69, 80) | 0.21 |
Concomitant cardiac medication/ | ||||
ACE-I/ARB, n (%) | 31 (76) | 17 (81) | 14 (70) | 0.48 |
Beta-blocker, n (%) | 39 (95) | 20 (95) | 19 (95) | 1 |
MRA, n (%) | 37 (90) | 19 (95) | 18 (86) | 0.6 |
Loop diuretics, n (%) | 38 (93) | 19 (91) | 19 (95) | 1 |
Biomarkers | ||||
eGFR, ml/min/1.73 m2 | 83 (71, 102) | 83 (73, 100) | 86 (71, 103) | 0.82 |
BNP, ng/l | 809 (79, 1523) | 300 (47, 851) | 1294 (506. 2920) | < 0.01 |
Troponin T, pg/ml | 29.1 (17.3, 46.5) | 23.6 (9.4, 41.7) | 33 (25.2, 65.2) | 0.09 |
Hemodynamic measurements | ||||
mPAP, mmHg | 28 (21, 38) | 23 (21, 34) | 33 (27, 40) | 0.09 |
Elevated mPAP (> 20 mmHg), n (%) | 33 (80) | 17 (81) | 16 (80) | 1 |
PCWP, mmHg | 19 (15, 27) | 17 (14, 22) | 22 (16, 33) | 0.18 |
Elevated PCWP (> 15 mmHg), n (%) | 27 (66) | 12 (57) | 15 (75) | 0.23 |
PVR, Wood units | 1.9 (1.2, 3.1) | 1.6 (1, 2.4) | 2.5 (1.8, 3.5) | < 0.05 |
Elevated PVR (≥ 3 Wood units), n (%) | 10 (25) | 3 (15) | 7 (35) | 0.14 |
Cardiac index, l/min/m2 | 2.3 ± 0.7 | 2.4 ± 0.6 | 2.2 ± 0.8 | 0.49 |